trending Market Intelligence /marketintelligence/en/news-insights/trending/bcwDZ8QJLftzJXfkNpPAfw2 content esgSubNav
In This List

Adamis resubmits new drug application to FDA for anaphylaxis treatment

Blog

Insight Weekly: US inflation soars; real estate faces slowdown; megadeals drive tech M&A

Blog

Commercial Banking: June 22nd Edition

Blog

Understanding Loss Given Default A Review of Three Approaches

Blog

Insight Weekly: Path to net-zero; US manufacturing momentum; China's lithium M&A frenzy


Adamis resubmits new drug application to FDA for anaphylaxis treatment

Adamis Pharmaceuticals Corp. resubmitted a new drug application to the U.S. FDA for epinephrine prefilled syringe product candidate for the emergency treatment of anaphylaxis, an extreme and severe allergic reaction.

The resubmission seeks to address issues raised by the agency in its June complete response letter.